Seattle Genetics (NASDAQ: SGEN) announced that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS (brentuximab vedotin) for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments

Needham & Company Reiterate Buy on Seattle Genetics (SGEN) Following Adcetris Approval August 18, 2015 11:12 AM Leerink Partners Remain Bullish on Seattle Genetics (SGEN) Following FDA's Approval of Adcetris August 18, 2015 10:13 AM Seattle Genetics Announces FDA Regular Approval of ADCETRIS® (Brentuximab Vedotin) for Classical Hodgkin Lymphoma Patients at High Risk of Relapse or Progression as Post-Autologous Hematopoietic StemAugust 17, 2015 4:08 PM